细胞角蛋白 19 片段 21.1、ERCC1、p53、FGFR3 和 TATI 作为生物标志物在膀胱癌中的诊断和预后潜能。
Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.
机构信息
Department of Urology, Collegium Medicum, University of Zielona Góra, 65-046 Zielona Góra, Poland.
出版信息
Int J Mol Sci. 2020 May 9;21(9):3360. doi: 10.3390/ijms21093360.
Abstract
The high occurrence of bladder cancer and its tendency to recur in combination with a lifelong surveillance make the treatment of superficial bladder cancer one of the most expensive and time-consuming. Moreover, carcinoma in situ often leads to muscle invasion with an unfavorable prognosis. Currently, invasive methods including cystoscopy and cytology remain a gold standard. The aim of this study was to explore urine-based biomarkers to find the one with the best specificity and sensitivity, which would allow optimizing the treatment plan. In this review, we sum up the current knowledge about Cytokeratin fragments (CYFRA 21.1), Excision Repair Cross-Complementation 1 (ERCC1), Tumour Protein p53 (Tp53), Fibroblast Growth Factor Receptor 3 (FGFR3), Tumor-Associated Trypsin Inhibitor (TATI) and their potential applications in clinical practice.
摘要
膀胱癌的高发生率及其复发倾向，再加上终生监测，使得表浅性膀胱癌的治疗成为最昂贵和最耗时的治疗之一。此外，原位癌常导致肌肉浸润，预后不良。目前，包括膀胱镜检查和细胞学检查在内的侵袭性方法仍然是金标准。本研究旨在探讨基于尿液的生物标志物，以找到特异性和敏感性最佳的标志物，从而优化治疗方案。在这篇综述中，我们总结了细胞角蛋白片段（CYFRA 21.1）、切除修复交叉互补基因 1（ERCC1）、肿瘤蛋白 p53（Tp53）、成纤维细胞生长因子受体 3（FGFR3）、肿瘤相关胰蛋白酶抑制剂（TATI）的最新知识及其在临床实践中的潜在应用。
相似文献
1
Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.细胞角蛋白 19 片段 21.1、ERCC1、p53、FGFR3 和 TATI 作为生物标志物在膀胱癌中的诊断和预后潜能。
Int J Mol Sci. 2020 May 9;21(9):3360. doi: 10.3390/ijms21093360.
2
Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.评估尿肿瘤相关胰蛋白酶抑制剂、细胞角蛋白19片段（CYFRA 21-1）及膀胱癌抗原用于检测高级别膀胱癌的情况。
Urology. 2008 Nov;72(5):1159-63. doi: 10.1016/j.urology.2008.04.009. Epub 2008 Jun 2.
3
Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.在接受根治性膀胱切除术的膀胱癌患者中，肿瘤相关胰蛋白酶抑制剂（TATI）和 p53 联合表达的预后价值。
Cancer Biomark. 2019;26(3):281-289. doi: 10.3233/CBM-182143.
4
FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.pTa和pT1期膀胱尿路上皮癌患者中FGFR3和p53蛋白的表达情况
Eur J Surg Oncol. 2006 Mar;32(2):231-7. doi: 10.1016/j.ejso.2005.11.018. Epub 2006 Jan 18.
5
Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer.肿瘤相关胰蛋白酶抑制剂作为膀胱癌随访期间的预后因素
Urology. 2003 Aug;62(2):249-53. doi: 10.1016/s0090-4295(03)00329-7.
6
Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.尿CYFRA 21.1在浅表性膀胱癌随访中并非检测复发的有用标志物。
Eur Urol. 2007 May;51(5):1267-74. doi: 10.1016/j.eururo.2006.12.019. Epub 2006 Dec 18.
7
Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression.原发性pT1期移行细胞膀胱癌中p53的免疫组织学表达与肿瘤进展的关系
Br J Urol. 1994 May;73(5):526-32. doi: 10.1111/j.1464-410x.1994.tb07638.x.
8
Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.尿液中肿瘤相关胰蛋白酶抑制剂（TATI）水平在膀胱移行细胞癌检测中的应用
Eur Urol. 2005 Sep;48(3):424-31. doi: 10.1016/j.eururo.2005.04.034.
9
P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder.膀胱pT1期移行细胞癌中P53表达、倍体与进展
Br J Urol. 1994 May;73(5):533-7. doi: 10.1111/j.1464-410x.1994.tb07639.x.
10
[Bladder tumor histo-seminar - case 6: Invasive urothelial carcinoma, with inverted growth (UroA/FGFR3 molecular type)].[膀胱肿瘤组织学研讨会 - 病例6：浸润性尿路上皮癌，呈内翻性生长（UroA/FGFR3分子类型）]
Ann Pathol. 2016 Dec;36(6):394-397. doi: 10.1016/j.annpat.2016.09.010. Epub 2016 Nov 9.
引用本文的文献
1
Severe Rectal Stenosis as the First Clinical Appearance of a Metastasis Originating from the Bladder: A Case Report and Literature Review.严重直肠狭窄作为膀胱转移瘤的首发临床表现：一例报告及文献复习
Life (Basel). 2025 Apr 22;15(5):682. doi: 10.3390/life15050682.
2
Diagnostic and Prognostic Potential of and in Muscle-Invasive Bladder Cancer.[具体物质名称]在肌层浸润性膀胱癌中的诊断和预后潜力
Int J Mol Sci. 2025 Apr 22;26(9):3959. doi: 10.3390/ijms26093959.
3
Bladder cancer biomarkers.膀胱癌生物标志物
Explor Target Antitumor Ther. 2025 Mar 25;6:1002301. doi: 10.37349/etat.2025.1002301. eCollection 2025.
4
BIN1 inhibited tumor growth, metastasis and stemness by ALDH1/NOTCH pathway in bladder carcinoma.在膀胱癌中，BIN1通过ALDH1/NOTCH信号通路抑制肿瘤生长、转移和干性。
Hereditas. 2025 Feb 27;162(1):29. doi: 10.1186/s41065-025-00384-w.
5
LncRNA Promotes Bladder Uroepithelial Cancer Progression by Stabilizing DDX5.长链非编码RNA通过稳定DDX5促进膀胱尿路上皮癌进展。
J Cancer. 2025 Jan 1;16(3):835-847. doi: 10.7150/jca.104034. eCollection 2025.
6
Enhanced Analytical Performance in CYFRA 21-1 Detection Using Lateral Flow Assay with Magnetic Bioconjugates: Integration and Comparison of Magnetic and Optical Registration.使用带有磁性生物共轭物的侧向流动分析法在细胞角蛋白19片段21-1检测中提高分析性能：磁性和光学记录的整合与比较
Biosensors (Basel). 2024 Dec 11;14(12):607. doi: 10.3390/bios14120607.
7
Prognostic model based on disulfidptosis-related lncRNAs for predicting survival and therapeutic response in bladder cancer.基于二硫键连接的细胞焦亡相关长链非编码RNA的膀胱癌生存及治疗反应预测模型
Front Immunol. 2024 Dec 2;15:1512203. doi: 10.3389/fimmu.2024.1512203. eCollection 2024.
8
Investigation on clinical risk factors of bladder lesion by machine learning based interpretable model.基于机器学习可解释模型的膀胱病变临床风险因素研究。
Sci Rep. 2024 Oct 16;14(1):24299. doi: 10.1038/s41598-024-75104-x.
9
Potential utility of ADNP in circulating tumor cells as biomarker for prognostics in non-muscle-invasive bladder cancer.ADNP 在循环肿瘤细胞中的潜在应用作为非肌肉浸润性膀胱癌预后的生物标志物。
Sci Rep. 2024 Aug 21;14(1):19352. doi: 10.1038/s41598-024-70379-6.
10
Photodynamic Diagnosis and Therapy in Non-Muscle-Invasive Bladder Cancer.非肌层浸润性膀胱癌的光动力诊断与治疗
Cancers (Basel). 2024 Jun 22;16(13):2299. doi: 10.3390/cancers16132299.
本文引用的文献
1
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
2
p53/PCDH17/Beclin-1 Proteins as Prognostic Predictors for Urinary Bladder Cancer.p53/PCDH17/Beclin-1蛋白作为膀胱癌的预后预测指标
J Cancer. 2019 Oct 15;10(25):6207-6216. doi: 10.7150/jca.37335. eCollection 2019.
3
Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.在接受根治性膀胱切除术的膀胱癌患者中，肿瘤相关胰蛋白酶抑制剂（TATI）和 p53 联合表达的预后价值。
Cancer Biomark. 2019;26(3):281-289. doi: 10.3233/CBM-182143.
4
Role of FGFR3 in Urothelial Carcinoma.成纤维细胞生长因子受体3（FGFR3）在尿路上皮癌中的作用。
Iran J Pathol. 2019 Spring;14(2):148-155. doi: 10.30699/IJP.14.2.148. Epub 2019 Jun 10.
5
Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study.低 ERCC1 表达是所有 TNM 分期的肺腺癌患者接受基于铂类化疗的良好预测标志物：一项单中心研究。
Diagn Pathol. 2019 Sep 14;14(1):105. doi: 10.1186/s13000-019-0885-2.
6
FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.成纤维细胞生长因子受体 3 突变通过抑制急性炎症增加膀胱癌发生。
J Pathol. 2018 Nov;246(3):331-343. doi: 10.1002/path.5143. Epub 2018 Sep 19.
7
Bladder Cancer: New Insights into Its Molecular Pathology.膀胱癌：对其分子病理学的新见解
Cancers (Basel). 2018 Apr 1;10(4):100. doi: 10.3390/cancers10040100.
8
A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer.DDX31/突变型 p53/EGFR 轴促进肌层浸润性膀胱癌的多步进展。
Cancer Res. 2018 May 1;78(9):2233-2247. doi: 10.1158/0008-5472.CAN-17-2528. Epub 2018 Feb 13.
9
Bladder cancer: Multi-omic profiling refines the molecular view.膀胱癌：多组学分析完善分子视角。
Nat Rev Clin Oncol. 2018 Apr;15(4):203-204. doi: 10.1038/nrclinonc.2017.195. Epub 2017 Dec 19.
10
ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.ERCC1 作为铂类化疗治疗晚期尿路上皮癌患者生存预后的预测因子：一项系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2017 Dec;120:120-126. doi: 10.1016/j.critrevonc.2017.10.012. Epub 2017 Nov 2.
Zotero 插件